Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes

Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.

Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.

In fact, nearly one in four diabetes patients take a gliptin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote